This is a specific type of cancer, often found in the ovary. It's a serious condition that needs medical attention.
Every report comes from a Lived member, sent anonymously.
Have you tried Carboplatin for Serous Cystadenocarcinoma?
Serous cystadenocarcinoma, now usually called serous carcinoma, is a cancer that grows from the thin lining cells of the ovary, fallopian tube or the peritoneum (the membrane that lines the abdomen). It is the most common type of ovarian cancer. Because these three sites share the same kind of lining tissue, doctors stage and treat serous cancers from any of them in the same way as ovarian cancer. There are two main forms, and they behave very differently. High-grade serous carcinoma is by far the more common. Many of these cancers are now thought to start in the end of the fallopian tube and shed cells into the abdomen early, which is why they are usually found after they have spread. Low-grade serous carcinoma is uncommon, tends to affect younger women, grows more slowly and has a better outlook, but responds less well to chemotherapy. Early on, serous carcinoma often causes no symptoms. When symptoms appear, they are easy to mistake for everyday digestive or bladder problems: bloating, swelling or pressure in the abdomen or pelvis, feeling full quickly, needing to urinate urgently or often, and changes such as constipation. Fluid can build up in the abdomen (ascites), making the belly swell.
Serous carcinoma develops when changes build up in the DNA of cells lining the tube, ovary or peritoneum. Most of these changes happen during a person's lifetime, and why they occur in one person and not another is usually unknown. The strongest known risk factor is an inherited variant in the BRCA1 or BRCA2 gene, which also raises the risk of breast cancer. Lynch syndrome, another inherited condition, raises risk too. A mother, sister or daughter with ovarian cancer increases a person's risk. Other associations include older age, especially after menopause, endometriosis, menopausal hormone therapy, obesity, being tall and never having been pregnant. These are associations, and most people with them never develop the disease. For people known to carry a BRCA variant, surgery to remove the ovaries and fallopian tubes at an age the care team recommends, usually once childbearing is complete, lowers the risk of ovarian cancer by about 80% to 90%, though a small risk of a similar cancer in the peritoneum remains.
Assessment usually starts with a pelvic exam, a transvaginal ultrasound and a blood test for CA-125 (cancer antigen 125), a protein that is often raised in serous cancer. CA-125 alone cannot diagnose cancer: it can also be raised by endometriosis and other noncancerous conditions, and it is not reliable for screening people at average risk. CT, MRI or PET scans show how far a suspected cancer has spread. The diagnosis is confirmed only when a pathologist examines tissue, either from a biopsy or from the surgery to remove the tumor. The pathologist also determines whether the cancer is high-grade or low-grade, which shapes treatment. Surgery and imaging together establish the stage, from stage I (confined to the ovaries or tubes) to stage IV (spread to distant organs, such as the lungs or the inside of the liver). Everyone diagnosed with this type of cancer should be offered genetic testing for BRCA1, BRCA2 and related genes, and tumor testing if no inherited variant is found. The results help decide which treatments fit, and an inherited variant also tells relatives about their own risk.
Treatment is usually led by a gynecologic oncologist, a surgeon who specializes in cancers of the female reproductive organs. For most high-grade serous cancers it combines surgery with chemotherapy. The goal of surgery, often called debulking, is to remove all visible cancer, which typically means removing the ovaries, tubes and uterus along with the omentum (a fatty apron of tissue in the abdomen) and any other affected tissue. How completely the visible cancer is removed is one of the strongest influences on outcome. Chemotherapy usually pairs a platinum drug such as carboplatin with paclitaxel. Some people have surgery first and chemotherapy afterward. Others, when the cancer is widespread or surgery is not safe right away, receive several cycles of chemotherapy first to shrink the cancer and then have surgery. Bevacizumab, a targeted infused drug that slows the growth of blood vessels feeding the tumor, is sometimes added. After chemotherapy works, many people with advanced disease take maintenance treatment with a PARP inhibitor, a daily pill that exploits a weakness in how some cancer cells repair DNA. Olaparib (Lynparza) is used for cancers with a BRCA variant, or together with bevacizumab when the cancer has a related DNA-repair defect called homologous recombination deficiency (HRD). Niraparib (Zejula) is used for HRD-positive cancers, which include those with a BRCA variant. In people with a BRCA variant, olaparib substantially delayed the cancer's return: three years after starting, about 60% were still free of progression, compared with 27% on placebo. It does not guarantee a cure. These drugs can cause fatigue, nausea and low blood counts, which need regular blood tests. Surgery is central for low-grade serous carcinoma, because it often responds poorly to chemotherapy, although chemotherapy may still be used. Hormone-blocking medicines are used after initial treatment or when it returns, and targeted drugs are another option. If either type of cancer returns, treatment depends on how long the previous response lasted: cancer that returns more than six months after platinum chemotherapy is usually treated with platinum again, while other drugs and clinical trials are options when it returns sooner.
Initial treatment usually takes several months, combining recovery from major abdominal surgery with chemotherapy given in repeated cycles. Fatigue is common through this period, and many people need help at home and time off work. Removing both ovaries usually brings on menopause symptoms for anyone who has not yet reached it, which is worth discussing beforehand, including fertility options when they matter. The outlook varies widely with the type and stage. Low-grade and early-stage cancers often do well over the long term. High-grade serous cancer is usually found at an advanced stage, and even after a good response it often returns. For many people it becomes a condition managed over years, with periods of treatment and periods off treatment, rather than a single course. After treatment, follow-up visits typically include exams, symptom review and often CA-125 blood tests, with scans when something changes. A rising CA-125 is often the first hint that cancer is returning. Starting treatment earlier on that basis alone, however, has not been shown to help people live longer, which is worth weighing with the care team. Support from palliative care, which focuses on symptoms and quality of life at any stage, genetic counselors and support groups can make a real difference.
See a clinician if bloating, pelvic or abdominal pain, feeling full quickly or urinary urgency is new for you and happens most days, rather than now and then. Ask about genetic counseling if close relatives have had ovarian, breast or related cancers. During chemotherapy, call your care team right away for a fever of 100.5°F (38°C) or higher, chills or other signs of infection, because chemotherapy lowers infection-fighting white blood cells. Call the care team the same day, or go to an emergency department if you cannot reach them that day, for repeated vomiting, cramping belly pain with a swollen, hard belly, being unable to pass stool or gas, or shortness of breath that has been building up. These can mean the bowel is blocked or fluid is building up in the abdomen or around the lungs, both common complications of advanced or returning serous cancer. Also call the same day about a painful, swollen leg, since blood clots are more likely after surgery and during treatment. Call 911 for sudden shortness of breath or chest pain, which can mean a clot has reached the lungs. Between visits after treatment, contact the team about gradually increasing abdominal swelling, persistent bloating or changes in bowel habits, since these can be signs the cancer has returned.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Serous Cystadenocarcinoma is like, what's helped you, or ask the community a question.